<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
		>
<channel>
	<title>Comments on: Dark Horse or Albatross?</title>
	<atom:link href="http://blog.pharmtech.com/2009/07/20/dark-horse-or-albatross/feed/" rel="self" type="application/rss+xml" />
	<link>http://blog.pharmtech.com/2009/07/20/dark-horse-or-albatross/</link>
	<description>The blog of Pharmaceutical Technology magazine</description>
	<lastBuildDate>Thu, 09 May 2013 23:30:55 -0400</lastBuildDate>
	<generator>http://wordpress.org/?v=2.8.4</generator>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
		<item>
		<title>By: Julian H</title>
		<link>http://blog.pharmtech.com/2009/07/20/dark-horse-or-albatross/comment-page-1/#comment-17691</link>
		<dc:creator>Julian H</dc:creator>
		<pubDate>Wed, 22 Jul 2009 08:31:23 +0000</pubDate>
		<guid isPermaLink="false">http://blog.pharmtech.com/?p=1550#comment-17691</guid>
		<description>Interesting, I hadn&#039;t seen this. Ranbaxy&#039;s prompt recalls of these drugs I think demonstrates that value of branding - they&#039;re clearly increasingly keen to protect their reputation, given the strained relationship with the FDA.</description>
		<content:encoded><![CDATA[<p>Interesting, I hadn&#8217;t seen this. Ranbaxy&#8217;s prompt recalls of these drugs I think demonstrates that value of branding &#8211; they&#8217;re clearly increasingly keen to protect their reputation, given the strained relationship with the FDA.</p>
]]></content:encoded>
	</item>
</channel>
</rss>
